Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics
Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies.
Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies.
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential